--- title: "BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-K: FY2025 Revenue: USD 6.162 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/283972914.md" datetime: "2026-04-24T09:41:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283972914.md) - [en](https://longbridge.com/en/news/283972914.md) - [zh-HK](https://longbridge.com/zh-HK/news/283972914.md) --- # BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-K: FY2025 Revenue: USD 6.162 M Revenue: As of FY2025, the actual value is USD 6.162 M. EPS: As of FY2025, the actual value is USD -8.66. EBIT: As of FY2025, the actual value is USD -10.55 M. #### Consolidated Revenue Consolidated revenue for bioAffinity Technologies, Inc. decreased by approximately 34% to $6.2 million in 2025, from $9.4 million in 2024, primarily due to strategic actions to discontinue unprofitable pathology services and reduce costs . #### CyPath® Lung Testing Revenue CyPath® Lung testing revenue increased by approximately 87% to $963,000 in 2025, compared to $516,000 in 2024 . The total number of CyPath® Lung test results delivered increased by 99%, exceeding 1,200 for 2025 . #### PPLS Revenue Breakdown - Patient service fees: $4,917,342 in 2025 vs. $8,175,670 in 2024 . - Histology service fees: $1,116,912 in 2025 vs. $1,103,751 in 2024 . - Medical director fees: $68,268 in 2025 vs. $66,576 in 2024 . - Department of Defense observational studies: $577 in 2025 vs. $8,654 in 2024 . - Other revenues: $4,860 in 2025 vs. $7,371 in 2024 . - Total net revenue: $6,161,959 in 2025 vs. $9,362,022 in 2024 . #### Operating Expenses Total operating expenses decreased by 9% to $16.7 million in 2025, compared to $18.3 million in 2024 . **Direct costs and expenses**: Decreased by approximately $1.8 million, or 29%, to $4.2 million in 2025 from $6.0 million in 2024 . **Research and development**: Remained consistent at $1.4 million in 2025 vs. $1.5 million in 2024 . **Clinical development**: Increased by approximately $384,000, or 119%, to $706,000 in 2025 from $322,000 in 2024 . **Selling, general and administrative**: Remained level at approximately $9.9 million for both 2025 and 2024 . **Depreciation and amortization**: Decreased by approximately $101,000, or 17%, to $505,000 in 2025 from $606,000 in 2024 . #### Other Income (Expense) Total other income (expense), net was - $4.3 million in 2025 compared to approximately - $75,000 in 2024 . This included: Interest (expense) income, net: - $20,987 in 2025 vs. - $74,865 in 2024 . Other (expense) income, net: - $461,939 in 2025 vs. $129 in 2024 . Gain (loss) on remeasurement of warrant liabilities: - $3,810,278 in 2025 vs. $0 in 2024 . #### Net Loss Net loss was - $14.9 million in 2025, compared to - $9.0 million in 2024 . #### Cash Flow - Net cash used in operating activities: - $9.3 million in 2025 vs. - $7.3 million in 2024, an increase of approximately $2.0 million in cash used . - Net cash used in investing activities: - $61,000 in 2025 vs. - $79,000 in 2024 . - Net cash provided by financing activities: $14.7 million in 2025 vs. $5.6 million in 2024 . - Cash and cash equivalents at end of year: $6.4 million in 2025 vs. $1.1 million in 2024 . #### Other Key Financial Metrics - Gross proceeds from equity transactions: Approximately $16.9 million raised in 2025 to fund operating activities . - Accumulated deficit: Approximately - $68.6 million as of December 31, 2025 . - Working capital surplus: $4.7 million as of December 31, 2025 . #### Outlook / Guidance bioAffinity Technologies, Inc. expects continued significant operating losses but anticipates increased revenue from accelerating CyPath® Lung sales and cost-saving measures . The company plans to expand CyPath® Lung into broader U.S. markets in 2026, including a longitudinal clinical trial, and aims to secure strategic partners for EU and Asia market entry . Management expects current cash resources to be sufficient through June 2026, but additional capital will be required for future operations and product development . ### Related Stocks - [BIAFW.US](https://longbridge.com/en/quote/BIAFW.US.md) ## Related News & Research - [bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 | BIAF Stock News](https://longbridge.com/en/news/286107351.md) - [Ta Yang exits loss-making UK unit but keeps London foothold via asset swap](https://longbridge.com/en/news/286588935.md) - [OMNICOM TO PRESENT AT THE J.P. MORGAN GLOBAL TECHNOLOGY, MEDIA AND COMMUNICATIONS CONFERENCE | OMC Stock News](https://longbridge.com/en/news/286281406.md) - [Phillips 66 Appoints Greg Hayes as Lead Independent Director | PSX Stock News](https://longbridge.com/en/news/286296547.md) - [BP Enters North Ustyurt PSA In Uzbekistan](https://longbridge.com/en/news/286207041.md)